Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-07-06 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a monthly update (as of June 30, 2022) detailing the total number of shares and the gross/net voting rights. This specific type of mandatory periodic disclosure regarding the capital structure and voting rights aligns best with a general regulatory filing or a specific capital structure update, but given the options, it is a mandatory disclosure about the composition of the capital and voting rights. While 'SHA' (Share Issue/Capital Change) is related, this is a recurring monthly disclosure of the *current* state, not an announcement of a specific change event. Since it is a mandatory regulatory disclosure that doesn't fit perfectly into the other specific categories (like 10-K, ER, DIV), it falls under the general regulatory filing category, RNS, or potentially a specific capital structure notification. Given the nature of reporting total voting rights monthly, it is a standard regulatory filing. However, since the content is purely about the capital structure (shares and voting rights), 'SHA' (Share Issue/Capital Change) is a plausible fit if interpreted broadly as 'Share Capital Information', but 'RNS' (Regulatory Filings) is the safest fallback for mandatory, non-financial periodic disclosures. Upon reviewing the definitions, there is no perfect fit for a 'Total Voting Rights Disclosure'. 'SHA' relates to changes, and this is a status report. Therefore, 'RNS' (Regulatory Filings) is the most appropriate general classification for this mandatory regulatory notice.
2022-07-06 French
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 1% confidence The document explicitly details 'Disclosure transaction in own shares' occurring between specific dates (27/06/2022 and 01/07/2022). It presents aggregated data showing the volume and price of shares acquired/transacted by the issuer (IPSEN). This content directly matches the definition for 'Transaction in Own Shares' (share repurchase/issuance), which corresponds to the filing code POS.
2022-07-05 English
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 27 Juin et 01 Juillet 2022" (Declaration of transactions on own shares carried out from June 27 and July 01, 2022). The content is a table detailing the volume, weighted average price, and date of transactions involving the company's own shares. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The appropriate code is POS.
2022-07-05 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 29, 2022, from Ipsen, written primarily in French, announcing that the US FDA has granted Priority Review to the New Drug Application (NDA) for palovarotene for treating Fibrodysplasia Ossificans Progressiva (FOP). It details regulatory milestones (FDA PDUFA date, Health Canada approval, EMA submission status) and provides background information on the drug and the disease. This type of announcement, focusing on regulatory progress and clinical development updates rather than full financial results (10-K, IR) or management changes (MANG), fits best under the general category for corporate news and regulatory updates. Since it is not a formal financial report, a transcript, or a specific governance document, and it is a substantive announcement rather than just a notice of publication (RPA), it falls under the broad 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant corporate news that doesn't fit the highly specific financial/governance codes. Given the context of a major regulatory update, RNS is the most appropriate fit among the provided options.
2022-06-29 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated June 29, 2022, announcing that the U.S. FDA has accepted for Priority Review the resubmitted New Drug Application (NDA) for palovarotene. It details the regulatory status, provides background on the drug and the disease (FOP), and includes forward-looking statements and contact information. This type of announcement, focusing on a specific regulatory milestone (NDA acceptance/review) for a drug, is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it is a formal announcement of a significant event/update rather than a full financial report (10-K, IR) or a transcript (CT), and it focuses on the immediate news, 'Earnings Release' (ER) is the most appropriate fit among the options for a major corporate update, even if it's not strictly tied to quarterly earnings figures. It is a high-impact, time-sensitive announcement intended for investors and the public.
2022-06-29 English
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 1% confidence The document explicitly details a 'Disclosure transaction in own shares' occurring between specific dates (20/06/2022 and 24/06/22). It provides aggregated data on the volume and price of shares acquired by the issuer (IPSEN). This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2022-06-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.